substance use disorder

The virtual opioid use disorder company reached profitability in Q4 2024, and expanded its team with the appointments of a chief operating officer and chief financial officer.

The funds will be used to increase product offerings, expand the commercial team and move into the substance use disorder space.  

The partnership gives Lantern clients entry into customized substance use disorder treatment and telemedicine services.  

The newly released PDTs, now RESET and RESET-O, deliver a self-directed, 12-week course of cognitive behavioral therapy that incentivizes patients to conform to treatment.

The alliance aims to mitigate the human and economic price related to the improper prescribing and dispensing of controlled substances.  

Dr. Yusuf Sherwani, CEO and cofounder of Pelago, describes how the company partners with employers and health plans to control the costs of substance misuse disorders and the effectiveness of the virtual evidence-based treatment platform.  

Marigold Health secures $11 million for AI-enabled peer support platform for mental health and substance use disorders.

The company offers a clinical vetting process and care-management pathway for individuals suffering from substance use disorders.

The recent investment brings the company's total raise to $151 million and will help it scale its offerings and conduct clinical research.

Bicycle Health CEO Ankit Gupta and Medical Director Dr. Brian Clear discuss the treatment landscape for patients with opioid use disorder.